The Experts below are selected from a list of 5325 Experts worldwide ranked by ideXlab platform
F. Fourrier - One of the best experts on this subject based on the ideXlab platform.
-
Hypophosphorémies en réanimation HypoPhosphatemia in the ICU
2003Co-Authors: C. Thomas, F. FourrierAbstract:HypoPhosphatemia is commonly observed in acutely ill patients. Several clinical situations may induce it. The decrease in Blood Phosphate Level may be due to an intracellular phosphorus shift and trapping or secondary to Phosphate depletion. When observed in insulin-treated diabetic ketoacidosis or after sustained respiratory alkalosis, hypoPhosphatemia is usually not complicated and improves spontaneously. On the other hand, Phosphate depletion may induce severe cardiac, respiratory and neuromuscular complications especially in alcoholic and long-starving patients, when refeeding uses a high carbohydrate diet or glucose infusion. Cytokine-induced hypoPhosphatemia may also occur in severe sepsis, septic shock and bacteremia. Although there is no general agreement in this field, Phosphate supplementation is indicated in malnourished and alcoholic patients, during exclusive parenteral nutrition or whatever the clinical situation, when Phosphate Blood Level has decreased below 10mg l. © 2003 Editions scientifiques et medicales Elsevier SAS. Tous droits reserves. Mots cles : Phosphore ; Hypophosphoremie ; Syndrome de renutrition ; Alcalose ventilatoire ; Sepsis
C. Thomas - One of the best experts on this subject based on the ideXlab platform.
-
Hypophosphorémies en réanimation HypoPhosphatemia in the ICU
2003Co-Authors: C. Thomas, F. FourrierAbstract:HypoPhosphatemia is commonly observed in acutely ill patients. Several clinical situations may induce it. The decrease in Blood Phosphate Level may be due to an intracellular phosphorus shift and trapping or secondary to Phosphate depletion. When observed in insulin-treated diabetic ketoacidosis or after sustained respiratory alkalosis, hypoPhosphatemia is usually not complicated and improves spontaneously. On the other hand, Phosphate depletion may induce severe cardiac, respiratory and neuromuscular complications especially in alcoholic and long-starving patients, when refeeding uses a high carbohydrate diet or glucose infusion. Cytokine-induced hypoPhosphatemia may also occur in severe sepsis, septic shock and bacteremia. Although there is no general agreement in this field, Phosphate supplementation is indicated in malnourished and alcoholic patients, during exclusive parenteral nutrition or whatever the clinical situation, when Phosphate Blood Level has decreased below 10mg l. © 2003 Editions scientifiques et medicales Elsevier SAS. Tous droits reserves. Mots cles : Phosphore ; Hypophosphoremie ; Syndrome de renutrition ; Alcalose ventilatoire ; Sepsis
Gaetano Serviddio - One of the best experts on this subject based on the ideXlab platform.
-
Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
Clinical Management Issues, 2015Co-Authors: Rosanna Villani, Roberta Forlano, Gianluigi Vendemiale, Gaetano ServiddioAbstract:INTRODUCTION: Tenofovir and entecavir are potent antiviral agents. By suppressing viral replication, they induce histological improvement and finally delay the progression of chronic hepatitis B and the development of complications. They are rarely associated with serious side effects. Our data from a real life experience support data from the literature and suggest some minimal difference that may be useful in tailoring therapy. PATIENTS AND METHODS: We retrospectively analyzed 54 patients affected by chronic hepatitis B (31 and 23 treated by entecavir and tenofovir, respectively). Eight patients were cirrhotic. At baseline and 4-12 and 24 weeks after starting therapy, biochemical and virological analysis were performed in all patients. Renal function tests (serum creatinine, creatinine clearance and Blood urea), serum (calcium and Phosphate Blood Level) and urine electrolyte were also studied. RESULTS: All the patients reached virological control within 24 weeks. Only in the group treated by tenofovir we observed a complete viral suppression within 12 weeks. Some patients treated with tenofovir showed increased creatinine clearance without serum creatinine alteration. No significant side effects were reported with the exception of one case of persistent headache in the entecavir group for which the drug was suspended. CONCLUSIONS: Entecavir and tenofovir are effective in suppressing viral replication in patients with chronic hepatitis B. Tenofovir is more potent than entecavir and viral replication is blocked within 12 weeks of therapy. Tenofovir administration is associated with slight increase of creatinine clearance without alteration of serum creatinine Levels. The choice of one or the other should be made according to target and specific patients characteristics. In patients with high serum viral load where the complete and quick control of viral replication is the main target, tenofovir may represent the best choice.
Rosanna Villani - One of the best experts on this subject based on the ideXlab platform.
-
Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
Clinical Management Issues, 2015Co-Authors: Rosanna Villani, Roberta Forlano, Gianluigi Vendemiale, Gaetano ServiddioAbstract:INTRODUCTION: Tenofovir and entecavir are potent antiviral agents. By suppressing viral replication, they induce histological improvement and finally delay the progression of chronic hepatitis B and the development of complications. They are rarely associated with serious side effects. Our data from a real life experience support data from the literature and suggest some minimal difference that may be useful in tailoring therapy. PATIENTS AND METHODS: We retrospectively analyzed 54 patients affected by chronic hepatitis B (31 and 23 treated by entecavir and tenofovir, respectively). Eight patients were cirrhotic. At baseline and 4-12 and 24 weeks after starting therapy, biochemical and virological analysis were performed in all patients. Renal function tests (serum creatinine, creatinine clearance and Blood urea), serum (calcium and Phosphate Blood Level) and urine electrolyte were also studied. RESULTS: All the patients reached virological control within 24 weeks. Only in the group treated by tenofovir we observed a complete viral suppression within 12 weeks. Some patients treated with tenofovir showed increased creatinine clearance without serum creatinine alteration. No significant side effects were reported with the exception of one case of persistent headache in the entecavir group for which the drug was suspended. CONCLUSIONS: Entecavir and tenofovir are effective in suppressing viral replication in patients with chronic hepatitis B. Tenofovir is more potent than entecavir and viral replication is blocked within 12 weeks of therapy. Tenofovir administration is associated with slight increase of creatinine clearance without alteration of serum creatinine Levels. The choice of one or the other should be made according to target and specific patients characteristics. In patients with high serum viral load where the complete and quick control of viral replication is the main target, tenofovir may represent the best choice.
Roberta Forlano - One of the best experts on this subject based on the ideXlab platform.
-
Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
Clinical Management Issues, 2015Co-Authors: Rosanna Villani, Roberta Forlano, Gianluigi Vendemiale, Gaetano ServiddioAbstract:INTRODUCTION: Tenofovir and entecavir are potent antiviral agents. By suppressing viral replication, they induce histological improvement and finally delay the progression of chronic hepatitis B and the development of complications. They are rarely associated with serious side effects. Our data from a real life experience support data from the literature and suggest some minimal difference that may be useful in tailoring therapy. PATIENTS AND METHODS: We retrospectively analyzed 54 patients affected by chronic hepatitis B (31 and 23 treated by entecavir and tenofovir, respectively). Eight patients were cirrhotic. At baseline and 4-12 and 24 weeks after starting therapy, biochemical and virological analysis were performed in all patients. Renal function tests (serum creatinine, creatinine clearance and Blood urea), serum (calcium and Phosphate Blood Level) and urine electrolyte were also studied. RESULTS: All the patients reached virological control within 24 weeks. Only in the group treated by tenofovir we observed a complete viral suppression within 12 weeks. Some patients treated with tenofovir showed increased creatinine clearance without serum creatinine alteration. No significant side effects were reported with the exception of one case of persistent headache in the entecavir group for which the drug was suspended. CONCLUSIONS: Entecavir and tenofovir are effective in suppressing viral replication in patients with chronic hepatitis B. Tenofovir is more potent than entecavir and viral replication is blocked within 12 weeks of therapy. Tenofovir administration is associated with slight increase of creatinine clearance without alteration of serum creatinine Levels. The choice of one or the other should be made according to target and specific patients characteristics. In patients with high serum viral load where the complete and quick control of viral replication is the main target, tenofovir may represent the best choice.